Klavocin (Amoxicillin, Clavulanic Acid)

Amoxicillin interferes with bacterial cell wall synthesis by binding to penicillin‑binding proteins, leading to cell lysis. Clavulanic acid inhibits beta‑lactamase enzymes produced by resistant bacteria, protecting amoxicillin from degradation and extending its antibacterial spectrum.

The prescribed dose of Klavocin is determined by the treating physician based on the type and severity of infection, patient age, weight, renal and hepatic function, and local antimicrobial guidelines. No fixed regimen is provided here.

Klavocin is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy or lactation when the potential benefit justifies the potential risk to the child.

To order Klavocin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Klavocin offers a beta‑lactam/beta‑lactamase inhibitor combination, providing coverage against many beta‑lactamase‑producing organisms that ceftriaxone may not target. Ceftriaxone, a third‑generation cephalosporin, has a longer half‑life allowing once‑daily dosing but lacks clavulanic acid’s protective effect. Choice depends on pathogen susceptibility, infection site, and patient factors.

Klavocin must be stored at 2‑8 °C in a refrigerator, protected from light, and should never be frozen or shaken. Prior to use, the solution should be inspected for particulate matter and discoloration, and prepared according to aseptic techniques recommended in the product labeling.

Klavocin is administered intravenously by slow infusion. The vial is reconstituted with the appropriate diluent, and the resulting solution is infused over the period specified by the prescribing clinician, typically ranging from 30 minutes to several hours depending on the dose and patient tolerance.

Serious adverse reactions include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, and rare cases of hepatic necrosis. Immediate medical attention is required if signs of severe allergic reaction, persistent diarrhea, or jaundice develop.

Patients with a documented hypersensitivity to amoxicillin, clavulanic acid, or any penicillin‑type antibiotics should avoid Klavocin. Caution is also advised for individuals with a history of severe liver disease, or those who have previously experienced severe reactions to beta‑lactamase inhibitor combinations.